Atlas Trials

Phase II Study of Durvalumab in Combination With Lenalidomide in Relapsed/Refractory NK-T-cell Lymphoma

Clinical trial NCT03054532 · UNKNOWN

Trial details

NCT number
NCT03054532
Sponsor
Singapore General Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
LYMPHOMA
Start date
2017-07-01
Primary completion
2021-01-01
Enrollment
22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.